F2G Tops Up Funds For Launch Of New Class Of Antifungal
UK Firm To Go It Alone With US Commercialization
Having banked a $100m upfront fee from licensing partner Shionogi a couple of months ago, F2G has now unveiled a $70m financing to advance its late-stage novel oral antifungal, olorofim.
You may also be interested in...
The UK firm has announced an extension of its series C financing which means it has raised just shy of $150m in the last 18 months to fund clinical development, manufacturing scale-up and preparations for the potential commercialization of opelconazole.
Olorofim employs a novel mechanism of action within the antifungal space and was tested in patients with high mortality risk who had exhausted treatment options.
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.